CD8A and neoplasm: In addition, low tumor mutational burden and the lack of CD8+ tumor-infiltrating lymphocytes in the tumor microenvironment in lung cancer with EGFR mutations may be possible explanations for the lack of efficacy of PD-L1 inhibitors (142).